Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

In advanced osteosarcoma where traditional chemotherapy has failed, the multi-targeted tyrosine kinase inhibitor apatinib has become a mainstream systemic treatment option in China. However, for patients with a high tumor burden or extra-pulmonary lesions, these drugs are prone to secondary resistance, necessitating combination with chemotherapy for more effective comprehensive control. Liposomal irinotecan, a newly approved topoisomerase inhibitor, exhibits lower toxicity compared to traditional irinotecan and is one of the second-line chemotherapy agents for osteosarcoma, making it a suitabl

Trial Details

NCT ID
NCT07479732
Phase
PHASE1 / PHASE2
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Liposomal Irinotecan
  • Apatinib in arm1
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • The subject or their legal representative must sign a written informed consent form prior to enrollment.
  • Diagnosis of refractory osteosarcoma confirmed by histopathology. Pathological confirmation is mandatory for localized tumors and isolated pulmonar…
  • Disease progression after standard, adequate first-line and second-line chemotherapy regimens for osteosarcoma, or progression within 6 months of s…
  • At least one measurable target lesion according to RECIST version 1.1 criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →